Clark & Stuart Inc Takes $202,000 Position in Repligen Co. (NASDAQ:RGEN)

Clark & Stuart Inc purchased a new position in shares of Repligen Co. (NASDAQ:RGEN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,400 shares of the biotechnology company’s stock, valued at approximately $202,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. UMB Bank n.a. raised its position in Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 130 shares during the last quarter. Blue Trust Inc. increased its stake in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 127 shares in the last quarter. Resources Management Corp CT ADV acquired a new position in shares of Repligen during the 3rd quarter worth approximately $37,000. Quarry LP lifted its stake in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 239 shares in the last quarter. Finally, nVerses Capital LLC acquired a new stake in Repligen during the 3rd quarter valued at $45,000. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on RGEN shares. Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Wolfe Research started coverage on shares of Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research report on Thursday, September 26th. Finally, Canaccord Genuity Group initiated coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and a consensus target price of $185.20.

Repligen Stock Up 0.1 %

Shares of RGEN opened at $154.86 on Monday. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company’s fifty day moving average is $146.77 and its two-hundred day moving average is $143.55. The firm has a market cap of $8.68 billion, a PE ratio of -418.53, a price-to-earnings-growth ratio of 4.64 and a beta of 0.97. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.09. The firm had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The firm’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.23 earnings per share. Analysts forecast that Repligen Co. will post 1.54 earnings per share for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.